Svend Kaasgaard, Skovlunde (DK); Jens Oebro, Humlebaek (DK); Signe Eskildsen Larsen, Kgs. Lyngby (DK); Allan Svendsen, Hoersholm (DK); Annette Helle Johansen, Broenshoej (DK); Michael Skjoet, Jyllinge (DK); Carsten Andersen, Vaerloese (DK); Lars Beier, Soeborg (DK); Esben Peter Friis, Herlev (DK); Miguel Duarte Guilherme Pereira Toscano, Frederiksberg (DK); Mads Bjoernvad, Virum (DK); Frank Winther Rasmussen, Roskilde (DK); and Liv Spaanger Christiansen, Gentofte (DK)
Assigned to Novozymes A/S, Bagsvaerd (DK)
Filed by Novozymes A/S, Bagsvaerd (DK)
Filed on Jul. 16, 2021, as Appl. No. 17/378,288.
Application 17/378,288 is a division of application No. 16/928,207, filed on Jul. 14, 2020, granted, now 11,091,748.
Application 16/928,207 is a division of application No. 16/190,580, filed on Nov. 14, 2018, granted, now 10,752,889, issued on Aug. 25, 2020.
Application 16/190,580 is a division of application No. 15/218,599, filed on Jul. 25, 2016, granted, now 10,167,458, issued on Jan. 1, 2019.
Application 15/218,599 is a division of application No. 14/129,565, granted, now 9,434,932, issued on Sep. 6, 2016, previously published as PCT/EP2012/062748, filed on Jun. 29, 2012.
Claims priority of provisional application 61/503,768, filed on Jul. 1, 2011.
Claims priority of application No. 11172251 (EP), filed on Jun. 30, 2011.
Prior Publication US 2021/0355470 A1, Nov. 18, 2021
1. An isolated variant of a parent alpha-amylase, comprising at least two substitutions at positions corresponding to positions 140 and 260 of the polypeptide of SEQ ID NO: 1, wherein the variant has at least 80% but less than 100% sequence identity with the polypeptide of any of SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 10, 11 or 12, and wherein the variant has alpha-amylase activity.